Stay updated with breaking news from Svb Securities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SVB Securities downgraded shares of Abcam (NASDAQ:ABCM – Free Report) from an outperform rating to a market perform rating in a research note published on Tuesday morning, FlyOnTheWall reports. Several other research firms have also commented on ABCM. Bank of America upgraded shares of Abcam from a neutral rating to a buy rating in a […]
SVB Securities downgraded shares of Abcam (NASDAQ:ABCM – Free Report) from an outperform rating to a market perform rating in a report released on Tuesday, FlyOnTheWall reports. A number of other equities analysts also recently issued reports on ABCM. William Blair downgraded Abcam from an outperform rating to a market perform rating in a research […]
SVB Securities cut shares of Selecta Biosciences (NASDAQ:SELB – Free Report) from an outperform rating to a market perform rating in a research report released on Friday, MarketBeat reports. The brokerage currently has $1.00 price objective on the stock. A number of other research firms also recently weighed in on SELB. TheStreet downgraded shares of […]
Viracta Therapeutics (NASDAQ:VIRX – Free Report) had its price target trimmed by SVB Securities from $10.00 to $5.00 in a report issued on Tuesday, MarketBeat Ratings reports. The firm currently has an outperform rating on the stock. Separately, HC Wainwright restated a buy rating and issued a $10.00 target price on shares of Viracta Therapeutics […]
Viracta Therapeutics (NASDAQ:VIRX – Get Free Report) had its price objective decreased by SVB Securities from $10.00 to $5.00 in a note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage presently has an “outperform” rating on the stock. SVB Securities’ price target suggests a potential upside of 322.94% from the company’s previous close. […]